New hope for rare blood vessel disorder: targeted drug shows promise
NCT ID NCT04258046
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug trametinib in 25 people aged 12 to 60 with complicated arteriovenous malformations (AVMs), which are abnormal blood vessel tangles that can cause pain, bleeding, and heart problems. The goal was to see if the drug could shrink the malformations and improve symptoms. Participants took trametinib pills daily, and doctors monitored their response using scans and quality-of-life measures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pediatric Dermatology Clinic at Stanford Children's Hospital
Palo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug shrink birthmarks? bleomycin injections put to the test
- Small study examines risks of injection treatment for Children's facial vein blemishes
- New hope for rare blood vessel disorders: everolimus trial launches
- Weekly pill could tame painful birthmarks with fewer side effects
- New registry sheds light on rare overgrowth diseases
- New hope for rare vascular malformations: targeted drugs enter trial